* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
Gut Podcast
The Gut Podcast is your go-to source for the latest discussions in gastroenterology and hepatology. Each month Dr. Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, dives into key issues in the field by discussing articles with their authors. Gut - gut.bmj.com - is an international journal from BMJ Group and the British Society of Gastroenterology (BSG) publishing research and review articles in gastroenterology and hepatology. Stay up to date with the latest research in gastroenterology. Subscribe to the Gut podcast.
Listen on:
Episodes
Friday Aug 15, 2014
Friday Aug 15, 2014
Despite the success of hepatitis B virus vaccination in preventing new infection in endemic areas, chronic hepatitis B still poses a heavy burden globally. There are approximately 350 million carriers in the world, with an estimated 60 000 persons dying annually of hepatitis B-related cirrhosis and hepatocellular carcinoma.
In a study recent published in Gut, Professor Man-Fung Yuen, Department of Medicine, The University of Hong Kong, and colleagues, report the results of viral suppression and safety of two doses of besifovir, with entecavir as a comparator in treatment-naive subjects for 48 weeks.
He talks to Mairi McLean about the findings.
Read the full paper:
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B http://gut.bmj.com/content/63/6/996.full
Monday Jun 09, 2014
Monday Jun 09, 2014
Mairi McLean talks to Robin Spiller, NIHR Nottingham Digestive Diseases Biomedical Research Unit, and David Tooth, School of Biomedical Sciences, University of Nottingham, about their paper: Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit.Read the full article: http://goo.gl/0OIP34
Tuesday Apr 29, 2014
Tuesday Apr 29, 2014
Mairi McLean talks to Andres Acosta and Barham K Abu Dayyeh, both Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, about their review on the management of obesity.Read the full paper: http://goo.gl/V37xaq
Friday Feb 21, 2014
Friday Feb 21, 2014
Necrotising enterocolitis (NEC) remains one of the primary causes of morbidity and mortality in neonates and alternative strategies are needed. Stem cells have become a therapeutic option for other intestinal diseases, which share some features with NEC. Along with colleagues, Simon Eaton and Paolo De Coppi, both from University College London Institute of Child Health, have tested the hypothesis that amniotic fluid stem (AFS) cells exerted a beneficial effect in a neonatal rat model of NEC.Mairi McLean discusses their findings with them.Read the full paper:Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism http://goo.gl/EFUuN0
Friday Jan 31, 2014
Friday Jan 31, 2014
Gut's education editor Mairi McLean discusses highlights from the guidelines on the diagnosis and management of Barrett's oesophagus with authors Rebecca Fitzgerald and Massimiliano di Pietro, both from the MRC Cancer Unit, University of Cambridge.Read the full paper here: http://bit.ly/1kkPkVW
Friday Nov 29, 2013
Friday Nov 29, 2013
Mairi McLean talks to Markus Peck-Radosavljevic, Division of Gastroenterology & Hepatology, Medical University Vienna, about his study looking at carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.Read the full paper here: bit.ly/1991biw
Friday Nov 15, 2013
Friday Nov 15, 2013
Mairi McLean talks to Anna Paterson and Rebecca Fitzgerald, both MRC Cancer Cell Unit, Hutchison-MRC Research Centre, Cambridge, about their study investigating whether a receptor tyrosine kinase (RTK) array could be used to select the most effective therapeutic strategies in molecularly heterogeneous oesophago-gastric adenocarcinomas.Read the full paper here: bit.ly/1acACwz
Tuesday Oct 22, 2013
Tuesday Oct 22, 2013
Fibrosis associated with chronic pancreatitis is an irreversible lesion that can disrupt pancreatic exocrine and endocrine function. Currently, there are no approved treatments for this disease.In this podcast Mairi McLean, Gut education editor, talks to Professor Yoshiro Niitsu from Sapporo Medical University School of Medicine about his manuscript about the potential for therapeutic use of siRNA in the treatment of pancreatic fibrosis.Read the full research online:http://gut.bmj.com/content/62/9/1328
Friday Aug 02, 2013
Friday Aug 02, 2013
Mairi McLean talks to Patrick Tan, associate professor, Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School Singapore, and Heike Grabsch, Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, University of Leeds, about their genomic meta-analysis to identify predictors of survival in patients with gastric cancer.See also: Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer http://goo.gl/Rw8lx6
Thursday Jul 25, 2013
Thursday Jul 25, 2013
Mairi McLean talks to Emeran Mayer, Oppenheimer Center for Neurobiology of Stress, Division of Digestive Diseases, UCLA, about his paper: An update on the use and investigation of probiotics in health and disease.Read the full paper here: http://bit.ly/11ghKss